Helix BioPharma Strengthens Leadership Team to Advance Oncology Research and Communication
TL;DR
Appointments of seasoned executives bring valuable experience and leadership to Helix BioPharma, enhancing competitive edge in oncology industry.
Veronika Kandziora and Jessica Kourniaktis join Helix BioPharma as COO and Director of Communications, respectively, to strengthen organizational structure and communication strategies.
Helix BioPharma's focus on developing novel therapies for hard-to-treat cancers aims to deliver better treatment options and improve patient outcomes, making the world a better place.
Ms. Kandziora's financial industry background and Ms. Kourniaktis' academic expertise bring diverse perspectives to Helix BioPharma, shaping a dynamic and innovative environment.
Found this article helpful?
Share it with your network and spread the knowledge!
Helix BioPharma Corp. has strengthened its leadership team with two strategic executive appointments designed to advance the company's oncology research and communication initiatives. Veronika Kandziora joins as Chief Operating Officer, bringing more than 20 years of leadership experience across biopharmaceutical, financial, and consulting sectors. Simultaneously, Dr. Jessica Kourniaktis assumes the role of Director of Communications with a decade of specialized experience in life sciences communication.
Kandziora's appointment provides significant institutional knowledge to Helix BioPharma, building on her previous roles as Corporate Secretary and strategic consultant to the company. Her extensive background in international finance and compliance positions her to deliver strategic alignment and operational strength across the organization. Kandziora's expertise encompasses complex international projects and includes advanced training in regulatory and governance environments, which will be crucial for navigating the pharmaceutical industry's compliance landscape.
Dr. Kourniaktis brings a distinctive background that merges academic research with strategic communications to her new position. Her professional experience includes founding a boutique consultancy, serving as an executive in multiple biopharmaceutical startups, and previously working as a Board Member of ESGTI AG. Her communications methodology is distinguished by analytical depth and compelling narrative development, with particular emphasis on articulating the vision and scientific merit of innovative medical ventures.
CEO Thomas Mehrling highlighted the strategic significance of these appointments, emphasizing that Kandziora's organizational leadership capabilities and Kourniaktis's strategy-first communications approach will be instrumental in progressing the company's mission to develop treatments for challenging cancer types. These leadership enhancements occur as Helix BioPharma focuses on its proprietary technology platform targeting CEACAM6-expressing solid tumors. The company's lead candidate, Tumour Defence Breaker™ L-DOS47, represents a clinical-stage antibody-enzyme conjugate engineered to neutralize tumor microenvironments and strengthen anti-cancer immune responses.
The executive appointments demonstrate Helix BioPharma's dedication to accelerating its oncology research programs while enhancing communication about its innovative cancer treatment methodologies. These strategic hires reflect a concerted effort to bolster the company's operational competencies and public engagement within the complex and highly competitive field of oncological drug development, particularly as the company advances its clinical pipeline targeting difficult-to-treat cancers.
Curated from NewMediaWire
